Welcome To SCAN-ACT

SCAN-ACT (Single Cell Analysis Network for Adoptive Cellular therapy Targets) is a computational pipeline developed by the Moding Lab and the Kalbasi Lab, and designed to identify adoptive T-cell therapy targets for solid tumors starting from single-cell RNA sequencing (scRNA-seq) data. SCAN-ACT was tested on 32 soft tissue sarcoma (STS) scRNA-seq samples to develop CellSARCTx (Cellular SARComa Therapy), a database of over 20,000 cellular therapy targets across 5 STS histotypes. This website allows the user to interactively explore STS cell therapy targets in CellSARCTx and to run custom analyses on any cancer of choice using SCAN-ACT.

Specifically, the website offers the following functionalities:

• Interactive exploration of monospecific and bispecific CAR-T cell targets, as well as TCR-T and Peptide-centric CAR-T targets in Synovial Sarcoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma, Liposarcoma, and Myxofibrosarcoma (CellSARCTx).
• Identification of tumor-specific up-regulated genes through differential gene expression analysis using user-provided scRNA-seq data from patients' samples (SCAN-ACT custom).
• Definition of monospecific and bispecific Boolean logic-gated CAR-T targets through integration of normal cells/tissues transcriptomics and proteomics with tumor-specific genomics and proteomics data, as well as CRISPR KO essentiality screens on cancer cell lines (SCAN-ACT custom).

SCAN-ACT Custom and CellSARCTx are freely available for academic use. Please register here.